GRK2 regulates ADP signaling in platelets via P2Y1 and P2Y12

Abstract

The critical role of G protein–coupled receptor kinase 2 (GRK2) in regulating cardiac function has been well documented for >3 decades. Targeting GRK2 has therefore been extensively studied as a novel approach to treating cardiovascular disease. However, little is known about its role in hemostasis and thrombosis. We provide here the first evidence that GRK2 limits platelet activation and regulates the hemostatic response to injury. Deletion of GRK2 in mouse platelets causes increased platelet accumulation after laser-induced injury in the cremaster muscle arterioles, shortens tail bleeding time, and enhances thrombosis in adenosine 5′-diphosphate (ADP)-induced pulmonary thromboembolism and in FeCl3-induced carotid injury. GRK2−/− platelets have increased integrin activation, P-selectin exposure, and platelet aggregation in response to ADP stimulation. Furthermore, GRK2−/− platelets retain the ability to aggregate in response to ADP restimulation, indicating that GRK2 contributes to ADP receptor desensitization. Underlying these changes in GRK2−/− platelets is an increase in Ca2+ mobilization, RAS-related protein 1 activation, and Akt phosphorylation stimulated by ADP, as well as an attenuated rise of cyclic adenosine monophosphate levels in response to ADP in the presence of prostaglandin I2. P2Y12 antagonist treatment eliminates the phenotypic difference in platelet accumulation between wild-type and GRK2−/− mice at the site of injury. Pharmacologic inhibition of GRK2 activity in human platelets increases platelet activation in response to ADP. Finally, we show that GRK2 binds to endogenous Gβγ subunits during platelet activation. Collectively, these results show that GRK2 regulates ADP signaling via P2Y1 and P2Y12, interacts with Gβγ, and functions as a signaling hub in platelets for modulating the hemostatic response to injury.

Novel Strategy to Combat the Procoagulant Phenotype in Heparin-Induced Thrombocytopenia Using 12-LOX Inhibition

“…To assess total platelet accumulation in the lung, mice were also given Alexa Fluor 750-labeled α-mouse GPIX to label platelets in vivo. The platelet-labeling antibody concentration does not cause thrombocytopenia or platelet aggregate accumulation in the lungs after intraperitoneal injection of saline (data not shown 31,32 ). Thirty minutes post-αCD9 administration, we assessed platelet count, body temperature, and lung thrombosis (Figure 2B through 2E).…”

Research Progress on the Mechanism of Salvia Miltiorrhiza Extract Inhibiting Platelet Aggregation

“…Platelets express the P2Y12 receptor on their surface, which is a G protein-coupled receptor. When the endothelium of blood vessels is damaged, collagen fibers are exposed, leading to the binding of the platelet surface receptor P2Y12 with ADP secreted by platelets, causing a change in platelet conformation and triggering platelet aggregation response [11] . In studies on the role of P2Y12 receptor signaling in the process of cardiac remodeling in mice, it was found that compared to wild-type mice, mice with P2Y12 gene knockout had significantly prolonged bleeding time and impaired platelet aggregation [12] .…”

Exploring bias in platelet P2Y1 signalling: Host defence versus haemostasis

“…tyrosine protein kinase [Src kinase] and G protein‐coupled receptor kinase 2/beta adrenergic receptor kinase 1 [GRK2] ) that balance platelet activation during normal haemostasis and thus, the interplay between these two receptors is defined as more than uni‐directional or comparative receptor density. Further, there is a need for operational balance after nucleotide activation (Hardy et al, 2004 , 2005 ; Zhao et al, 2022 ). Cooperativity can also occur between P2Y 1 and the ATP‐gated ion channel P2X 1 (Jones et al, 2014 ; Tolhurst et al, 2005 ; Vial et al, 2002 ).…”